[LCID Study Number: 2018-026]
S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, with or without Brain Metastases
The primary objective in this study is to compare the efficacy of cisplatin with or without ABT-888 (veliparib) on progression-free survival (PFS) in each of the following groups: 1. Patients with germline BRCA (gBRCA) mutation-associated breast cancer 2. Patients with germline BRCA wild-type breast cancer who have evidence of BRCAness phenotype 3. Patients with germline BRCA wild-type breast cancer who do not have evidence of BRCAness phenotype.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-3071